Vascular Endothelial Growth Factor (VEGF)-B Blockade with CSL346 in Diabetic Kidney Disease: A Phase 2A Randomized Controlled Trial.
Melisa CooperDavid Z I CherneyTom H GreeneHiddo J Lambers HeerspinkMeg J JardineJulia B LewisMuh Geot WongElbalejandra BaqueroMark HeiseJeanine JochemsDiana LanchoneyCharles LissDavid ReiserPierre ScotneyElena VelkoskaJamie P DwyerPublished in: Journal of the American Society of Nephrology : JASN (2024)
CSL346 did not reduce UACR compared with placebo at 16 weeks in participants with type 2 diabetes mellitus and DKD, and was associated with an increase in diastolic blood pressure.